临床神经外科杂志2016，Vol.13Issue(5)：328-331,4.DOI:10.3969/j.issn.1672-7770.2016.05.003
伽玛刀联合贝伐单抗治疗颅内恶性胶质瘤的疗效分析
Outcome analysis on gamma knife and bevacizumab against intracranial malignant ;gliomas
摘要
Abstract
Objective To compare the outcome of recurrent or residue malignant patients underwent Gama knife radiosurgery combined with or without bevacizumab.Methods 83 patients with malignant glioma, admitted from 2012 to 2015, were enrolled in this study.40 patients were treated with combined therapy of Gamma knife and bevacizumab, and 43 with Gamma knife only. All these patients were followed up and analyzed by response rate and survival.Results All patients were followed up from 4 to 42 months and their response rate, survival and KPS were recorded.6-month response rate was 92.50% in combined therapy group and 74.42% in Gamma knife group ( P<0.05 ) .1-year survival and 20-month survival were 72.58% and 56.42% in combined therapy group, while 32.15%and 14.40%in Gamma knife group (P<0.05).Meanwhile KPS in combined therapy group was significantly higher than that in Gamma knife group (P <0.05). Conclusion Combined therapy with Gamma Knife and bevacizumab was safe and effective for intracranial malignant glioma, which improves the response rate, survival and KPS significantly.关键词
伽玛刀/贝伐单抗/脑恶性胶质瘤Key words
gamma knife/Bevacizumab/malignant brain glioma分类
医药卫生引用本文复制引用
马亮,傅相平,赵明,王晓朋,张志文..伽玛刀联合贝伐单抗治疗颅内恶性胶质瘤的疗效分析[J].临床神经外科杂志,2016,13(5):328-331,4.基金项目
首都临床特色临床应用研究基金（ Z131107002213177）；首都医学发展基金 （）
